论文部分内容阅读
目的探讨切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)在人非小细胞肺癌(non-small cell lung cancer NSCLC)癌组织和外周血淋巴细胞(peripheral blood lymphocyte,PBL)中的表达及其相关性,以期建立临床实用简便的肿瘤学指标。方法采用间接二步法免疫荧光化学染色检测47例Ⅱ期、Ⅲ期NSCLC患者癌组织和PBL中ERCC1的表达及健康人PBL中ERCC1的表达。结果ERCC1在癌组织、NSCLC患者PBL和健康人PBL中的表达分别为53.19%(25/47)、48.94%(23/47)和20%(4/20),其中癌组织的ERCC1表达与NSCLC患者PBL的表达呈正相关,20例健康人PBL的ERCC1表达阳性率显著低于NSCLC患者。ERCC1的表达与临床病理类型无关。结论检测NSCLC患者PBL的ERCC1表达可间接反应癌组织的ERCC1表达状况。
OBJECTIVE: To investigate the effect of excision repair cross-complementation group 1 (ERCC1) in non-small cell lung cancer (NSCLC) and peripheral blood lymphocytes (PBL) Expression and its correlation, in order to establish clinical practical and convenient oncology index. Methods Indirect two-step immunofluorescence staining was used to detect the expression of ERCC1 and the expression of ERCC1 in PBL of 47 patients with stage Ⅱ and Ⅲ NSCLC. Results The expression of ERCC1 was 53.19% (25/47), 48.94% (23/47) and 20% (4/20) respectively in cancerous tissues, NSCLC patients and PBLs. The expression of ERCC1 in cancerous tissues and NSCLC The expression of PBL in patients was positively correlated, and the positive rate of ERCC1 expression in PBL of 20 healthy people was significantly lower than that in NSCLC. The expression of ERCC1 has nothing to do with the clinicopathological type. Conclusion Detection of ERCC1 expression in PBL of NSCLC patients can indirectly reflect the expression of ERCC1 in cancer tissues.